Great Point Partners Makes Growth Investment in iXCells Biotechnologies
September 29, 2022
Great Point Partners, a Greenwich, CT-based healthcare-focused private investment firm, has made a growth investment in San Diego-based iXCells Biotechnologies. The capital will be used to expand iXCells' operational capacity, broaden its product and service offering (including bioanalytical capabilities) and support growth into adjacent high-growth end markets such as personalized medicine and rare disease research.
- Buyers
- Great Point Partners
- Targets
- iXCells Biotechnologies
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Ampersand Capital Partners Makes Growth Investment in VIVEbiotech
December 4, 2024
Biotechnology
Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.
-
HealthQuest Capital and Great Point Partners Invest Growth Equity in Cellipont Bioservices; Darren Head Named CEO
October 7, 2024
Biotechnology
Cellipont Bioservices named Darren Head as CEO and announced a minority growth equity investment from HealthQuest Capital, with majority investor Great Point Partners also participating. The capital and leadership transition are intended to support Cellipont’s expansion of cell-therapy CDMO capabilities and operational growth.
-
Great Point Partners Makes Growth Investment in Ephicacy Consulting Group
July 21, 2022
Healthcare Services
Great Point Partners completed a growth investment in Ephicacy Consulting Group, a biometrics contract research organization (CRO) that provides statistical programming, data management, and real-world evidence analytics. The minority growth capital partnership will support Ephicacy's accelerated growth across its operations in the United States, Canada, and India and expand its clinical analytics capabilities.
-
Galapagos NV Acquires CellPoint and AboundBio
June 21, 2022
Biotechnology
Galapagos NV has acquired CellPoint and AboundBio to accelerate access to next-generation cell therapies, combining CellPoint's decentralized point-of-care CAR-T manufacturing platform with AboundBio's fully human antibody discovery capabilities. The deal includes an upfront €125 million for CellPoint (plus up to €100 million in milestones) and $14 million for AboundBio, positioning Galapagos to expand its cell therapy pipeline and validate a rapid vein-to-vein delivery model.
-
Great Point Partners Completes Growth Recapitalization of Velentium
September 29, 2021
Medical Devices
Great Point Partners completed a growth recapitalization of Houston-based Velentium, a professional engineering and contract medical device manufacturer. The investment will fund Velentium's expansion initiatives — including tuck-in acquisitions and enhanced engineering and manufacturing capabilities — while preserving the company's quality and culture.
-
Catalent Acquires MaSTherCell Global from Great Point Partners and Co-investors
February 3, 2020
Biotechnology
Catalent Pharma Solutions has signed a definitive agreement to acquire MaSTherCell Global, a cell and gene therapy CDMO that Great Point Partners had invested in alongside Orgenesis and SFPI-FPIM. MaSTherCell, headquartered in Gosselies, Belgium with a U.S. facility in Houston, Texas, expands Catalent's cell and gene therapy development and manufacturing capabilities and adds significant European and U.S. capacity.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.